Johnson & Johnson (France)

Recent papers from Johnson & Johnson (France)

1. The Accumulation of Healthcare, Benefit and Social Care Costs of Depression Before and After Diagnosis: A Six-Year Observational Cohort StudyPharmacoEconomics · 2026
2. Velocity vector analysis for slowly conducting anatomical isthmuses in patients with tetralogy of FallotHeart Rhythm · 2026
3. Patient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravisBMC Neurology · 2026
4. Long‑term disease control in generalized myasthenia gravis: a systematic literature reviewBMC Neurology · 2026
5. Real-world Clinical Effectiveness of Guselkumab and Its Impact on Quality of Life and Sexual Quality of Life in Patients with Genital Psoriasis: Results from the CASSIOPEE StudyBritish Journal of Dermatology · 2026
6. Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialNature Medicine · 2026
7. Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialNature Medicine · 2026
8. P50 | Inpatient vs. Outpatient Treatment Management With Teclistamab in Relapsed and Refractory Multiple Myeloma: A Cost and Healthcare Resource Utilization AnalysisSHILAP Revista de lepidopterología · 2026
9. REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsHaematologica · 2026
10. Neoadjuvant (Neoadj) gemcitabine intravesical system (Gem-iDRS) plus cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for/refusing neoadj cisplatin-based chemotherapy (NAC): Updated perioperative outcomes from SunRISe-4.Journal of Clinical Oncology · 2026
11. Optimising Investment in Health Innovations in EuropeJournal of Market Access & Health Policy · 2026
12. Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS StudyRheumatology and Therapy · 2026
13. European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaClinical Lymphoma Myeloma & Leukemia · 2025
14. First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.Blood · 2025
15. A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort aBlood · 2025
16. Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysisBlood · 2025
17. Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4Journal of Clinical Oncology · 2025
18. A Systematic Literature Review Exploring the Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial HypertensionPulmonary Circulation · 2025
19. Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.2025
20. Real‐World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic LandscapeJournal of the Peripheral Nervous System · 2025